Arterial hypertension in gravidity – a risk factor for cardiovascular diseases
Authors:
M. Kováčová; S. Kiňová
Authors place of work:
I. interná klinika Lekárskej fakulty UK a UN Bratislava, Slovenská republika, prednostka doc. MUDr. Soňa Kiňová, PhD.
Published in the journal:
Vnitř Lék 2012; 58(12): 922-927
Category:
Review
Summary
Gravidity is a dynamic process and complications may occur at any stage and anytime during a thus far physiological gravidity. Such gravidity puts the mother, the foetus and, later, the newborn at a greater risk. The incidence of arterial hypertention is between 7 and 15% and is one of the 4 main causes of maternal and perinatal mortality. Cardiovascular stress test, such as gravidity, might help to identify women at a greater risk of cardiovascular diseases or with a subclinical vascular disease. Women with a history of preeclampsia are more likely to develop chronic arterial hypertension in the future either alone or associated with a cardiovascular disease. Arterial hypertension during gravidity should be considered as a risk factor for cardiovascular diseases during later stages of maternal life. Prevention of cardiovascular diseases should be a life-long aspiration.
Key words:
arterial hypertension in gravidity – preeclampsia – endothelial dysfunction – cardiovascular risk
Zdroje
1.Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. Bratislava: Univerzita Komenského – Vydavateľstvo UK 2001: 268 s.
2. Janků K, Janků P, Hofírek I et al. Kardiovaskulární choroby v těhotenství. Brno: Masarykova Univerzita 2005: 320 s.
3. Koucký M. Současný pohled na léčbu hypertenze v těhotenství. Vnitř Lék 2011; 57: 728–731.
4. Regitz-Zagrosek V, Blomstrom Lundquist C, Borghi C et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 2011; 32: 3147–3197.
5. Hájek Z, Andělová K, Binder T et al. Rizikové a patologické těhotenství. Praha: Grada Publishing 2004: 444 s.
6. Fedelešová V. Liečba hypertenzie v tehotenstve. Via Practica 2004; 3: 151–154.
7. Cífková R. Hypertenze v těhotenství. Čas Lék Česk 2009; 148: 65–71.
8. Sirotiaková J, Dukát A, Mlynček M. Manažment artériovej hypertenzie v gravidite. Kardio prax 2004; 2: 86–91.
9. Cífková R. Hypertenze v těhotenství. Vnitř Lék 2006; 52: 263–270.
10. Rossi, GP, Seccia, TM, Pessina AC. Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci 2007; 44: 1–85.
11. Grodski S, Jung C, Kertes P. Phaeochromocytoma in pregnancy. Intern Med J 2006; 36: 604–606.
12. Janků P, Janků K, Unzeitig V. Preeklampsie z hlediska mezioborové spolupráce. Vnitř Lék 2009; 55: 1159–1160.
13. Myatt L, Webster RP. Vascular biology of preeclampsia. J Thromb Haemost 2009; 7: 375–384.
14. Murín B, Lukačín Š. Etiopatogenéza, rizikové faktory a klasifikácia preeklampsie. Gynekol prax 2006; 4: 8–12.
15. Šimetka O, Brychtová P, Procházková J et al. Laboratorní změny aktivace endotelu u syndromu HELLP. Gynekolog 2008; 17: 54–56.
16. Gavorník P. Vaskulárna endotelová dysfunkcia – etiopatogenéza, základné diagnostické metódy a liečebné možnosti. Gen Angiol 2002; 2: 59–66.
17. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002; 287: 3183–3186.
18. Holomáň K, Bieliková E, Černák V et al. Vybrané kapitoly z pôrodníctva. Bratislava: Univerzita Komenského v Bratislave 2004: 444 s.
19. Walsh SW. Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids 2004; 70: 223–232.
20. Vadillo-Ortega F, Perichart-Perera O, Espino S et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 2011; 342: d2901.
21. Jabor A, Hornová L, Fantová L, Engliš M. Vyšetření funkce ledvin: možnosti biochemické laboratoře. Postgrad Med 2006; 8: 18–22.
22. Gangaram R, Naicker M, Moodley J. Comparison of pregnancy outcomes in women with hypertensive disorders of pregnancy using 24-hour urinary protein and urinary microalbumin to creatinine ratio. Int J Gynaecol Obstet 2009; 107: 19–22.
23. Monhart V. Mikroalbuminurie. Od diabetu ke kardiovaskulárnímu riziku. Vnitř Lék 2011; 57: 293–298.
24. Baker AM, Klein RL, Moss KL, Haeri S, Bogges K. Maternal serum dyslipidemia occurs early in pregnancy in women with mild but not severe preeclampsia. Am J Obstet Gynecol 2009; 201: 293–295.
25. O‘Brien TE, Ray JG, Chan WS. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003; 14: 368–374.
26. Weiss JL, Malone FD, Emig D et al. Obesity, obstetric complications and cesarean delivery rate – a population-based screening study. Am J Obstet Gynecol 2004; 190: 1091–1097.
27. Wagner SJ, Barac S, Garovic VD. Hypertensive pregnancy disorders. J Clin Hypertens (Greenwich) 2007; 9: 560–566.
28. Buemi M, Bolignano D, Barilla A et al. Preeclampsia and cardiovaskular risk: general characteristic, counseling and follow-up. J Nephrol 2008; 21: 663–672.
29. Paarlberg KM, Vingerhoets AJ, Passchier J et al. Psychosocial predictors of low birthweight: a prospective study. Br J Obstet Gynaecol 1999; 106: 834–841.
30. Nissel H, Lintu H, Lunell NO, Möllerström G, Petterson E. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br J Obstet Gynaecol 1995; 102: 876–881.
31. Wilson BJ, Stuart WM, Prescott GJ et al. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. BMJ 2003; 326: 845.
32. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. BMJ 2001; 323: 1213–1217.
33. Melchiorre K, Thilaganathan B. Maternal cardiac function in preeclampsia. Curr Opin Obstet Gynecol 2011; 23: 440–447.
34. Roes EM, Raijmakers MT, Roelofs HM, Peters WH, Steegers EA. Urinary GSTP1-1 excretion is markedly increased in normotensive pregnancy as well as in preeclampsia. J Nephrol 2005; 18: 405–408.
35. Shammas AG, Maayah JF. Hypertension and its relation to renal function 10 years after pregnancy complicated by preeclampsia and pregnancy induced hypertension. Saudi Med J 2000; 21: 190–192.
36. Bar J, Kaplan B, Wittenberg C et al. Microalbuminuria after pregnancy complicated by pre-eclampsia. Nephrol Dial Transplant 1999; 14: 1129–1132.
37. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med 2008; 359: 800–809.
38. Perk J, De Backer G, Gohlke H et al. European Guidelines on cardiovascular disease prevention in clinical practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2012; 33: 1635–1701.
Štítky
Diabetology Endocrinology Internal medicineČlánok vyšiel v časopise
Internal Medicine
2012 Číslo 12
Najčítanejšie v tomto čísle
- Arterial hypertension in gravidity – a risk factor for cardiovascular diseases
- Current opinions on gout, its diagnosis and treatment
- Current guidelines on the care of tunelized vascular catheters in patients on home parenteral nutrition
- Is antiplatelet therapy always effective?